NASDAQ:INVA Innoviva - INVA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.65 +0.17 (+1.36%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$12.51▼$12.6650-Day Range$12.42▼$13.6452-Week Range$11.56▼$20.71Volume447,286 shsAverage Volume616,064 shsMarket Capitalization$882.72 millionP/E Ratio3.97Dividend YieldN/APrice Target$13.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Innoviva MarketRank™ ForecastAnalyst RatingHold1.50 Rating ScoreUpside/Downside2.8% Upside$13.00 Price TargetShort InterestBearish13.71% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth-68.86%From $3.34 to $1.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.30 out of 5 starsMedical Sector1022nd out of 1,055 stocksPharmaceutical Preparations Industry501st out of 518 stocks 0.8 Analyst's Opinion Consensus RatingInnoviva has received a consensus rating of Hold. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Innoviva has a forecasted upside of 2.8% from its current price of $12.65.Amount of Analyst CoverageInnoviva has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.71% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently decreased by 4.16%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 3.1 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Innoviva this week, compared to 2 articles on an average week.Search Interest9 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows2 people have added Innoviva to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.89% of the stock of Innoviva is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Innoviva are expected to decrease by -68.86% in the coming year, from $3.34 to $1.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 3.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 3.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 158.52.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Innoviva (NASDAQ:INVA) StockInnoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.Read More Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address INVA Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Price Target Lowered to $13.00 at Morgan StanleyDecember 28, 2022 | finance.yahoo.comInnoviva (INVA) Stock Moves -1.06%: What You Should KnowJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 28, 2022 | finance.yahoo.comDo Its Financials Have Any Role To Play In Driving Innoviva, Inc.'s (NASDAQ:INVA) Stock Up Recently?December 19, 2022 | msn.comInnoviva Earnings Perspective: Return On Capital EmployedNovember 30, 2022 | finance.yahoo.comInnoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)November 11, 2022 | finance.yahoo.comInnoviva Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 9, 2022 | finance.yahoo.comInnoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 9, 2022 | finance.yahoo.comInnoviva (INVA) Q3 Earnings and Revenues Lag EstimatesOctober 19, 2022 | finance.yahoo.comInnoviva (INVA) Earnings Expected to Grow: Should You Buy?October 19, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022 - Yahoo FinanceOctober 19, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022October 14, 2022 | finance.yahoo.comLa Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022 - Yahoo FinanceOctober 14, 2022 | businesswire.comLa Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022 - Business WireOctober 14, 2022 | nasdaq.comValidea John Neff Strategy Daily Upgrade Report - 10/11/2022 - NasdaqOctober 12, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022 - Yahoo FinanceOctober 12, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022October 9, 2022 | nasdaq.comInvestors who have held Innoviva (NASDAQ:INVA) over the last year have watched its earnings decline along with their investment - NasdaqSeptember 29, 2022 | finance.yahoo.comGate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update - Yahoo FinanceSeptember 27, 2022 | reuters.comINVA.OQ - Innoviva Inc | Stock Price & Latest News | ReutersSeptember 19, 2022 | seekingalpha.comInnoviva Stock? Not Yet. Short Puts? Definitely. (NASDAQ:INVA) - Seeking AlphaSeptember 8, 2022 | businesswire.comInnoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Business WireAugust 29, 2022 | globenewswire.comChronic Obstructive Pulmonary Disease Drug Market exhibiting a CAGR of 6.8 % and is expected to reach USD 1.6 Billion by 2029 - GlobeNewswireAugust 23, 2022 | benzinga.comInnoviva Completes Acquisition of La Jolla...August 22, 2022 | businesswire.comInnoviva Completes Acquisition of La Jolla Pharmaceutical - Business WireAugust 1, 2022 | benzinga.comInnoviva's Return On Capital Employed Overview - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address INVA Company Calendar Last Earnings11/09/2022Today1/31/2023Next Earnings (Estimated)2/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees5Year Founded1996Price Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+2.8%Consensus RatingHold Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$3.19 Trailing P/E Ratio3.97 Forward P/E Ratio3.79 P/E GrowthN/ANet Income$265.85 million Net Margins78.39% Pretax Margin109.35% Return on Equity23.89% Return on Assets12.13% Debt Debt-to-Equity Ratio0.69 Current Ratio2.77 Quick Ratio2.34 Sales & Book Value Annual Sales$391.87 million Price / Sales2.25 Cash Flow$4.62 per share Price / Cash Flow2.74 Book Value$7.56 per share Price / Book1.67Miscellaneous Outstanding Shares69,780,000Free Float69,162,000Market Cap$882.72 million OptionableOptionable Beta0.55 Social Links Key ExecutivesPavel RaifeldChief Executive OfficerSusan LendertsDirector-Strategic Marketing & AnalyticsMarianne ZhenSecretary & Chief Accounting OfficerKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTOPKO HealthNASDAQ:OPKImmunoGenNASDAQ:IMGNEmergent BioSolutionsNYSE:EBSAVEO PharmaceuticalsNASDAQ:AVEOView All CompetitorsInsiders & InstitutionsSummit Global InvestmentsSold 1,941 shares on 1/31/2023Ownership: 0.198%New York State Common Retirement FundBought 17,487 shares on 1/30/2023Ownership: 0.313%James Investment Research Inc.Bought 12,478 shares on 1/30/2023Ownership: 0.114%Kendall Capital ManagementBought 2,695 shares on 1/30/2023Ownership: 0.058%Versor Investments LPSold 27,054 shares on 1/30/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions INVA Stock - Frequently Asked Questions Should I buy or sell Innoviva stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares. View INVA analyst ratings or view top-rated stocks. What is Innoviva's stock price forecast for 2023? 2 brokers have issued 1 year target prices for Innoviva's stock. Their INVA share price forecasts range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next year. This suggests a possible upside of 2.8% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts. How have INVA shares performed in 2023? Innoviva's stock was trading at $13.25 on January 1st, 2023. Since then, INVA shares have decreased by 4.5% and is now trading at $12.65. View the best growth stocks for 2023 here. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, November, 9th. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.75 by $2.15. The biotechnology company had revenue of $67.26 million for the quarter, compared to the consensus estimate of $361.45 million. Innoviva had a trailing twelve-month return on equity of 23.89% and a net margin of 78.39%. What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." Who are Innoviva's major shareholders? Innoviva's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.45%), Allspring Global Investments Holdings LLC (0.39%), New York State Common Retirement Fund (0.31%), Exchange Traded Concepts LLC (0.22%), Summit Global Investments (0.20%) and James Investment Research Inc. (0.11%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $12.65. How much money does Innoviva make? Innoviva (NASDAQ:INVA) has a market capitalization of $882.72 million and generates $391.87 million in revenue each year. The biotechnology company earns $265.85 million in net income (profit) each year or $3.19 on an earnings per share basis. How can I contact Innoviva? Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690. This page (NASDAQ:INVA) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.